Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell
transplantation (ASCT) has established itself as a core treatment for newly diagnosed …

The introduction of high-dose therapy in the 1990s as well as the development of drugs such
as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive …

High-dose melphalan supported by autologous transplantation has been the standard of
care for eligible patients with newly diagnosed multiple myeloma (MM) for> 25 years …

Multiple myeloma (MM) is the second most common hematologic malignancy with an
increasing incidence and prevalence. The wide array of effective antimyeloma agents have …

In multiple myeloma impressive outcomes have improved with the introduction of new
therapeutic approaches, mainly those including naked monoclonal antibodies such as …

Multiple myeloma (MM) is the second most common hematologic malignancy. The diagnosis
of MM requires⩾ 10% clonal plasma cells in the bone marrow or biopsy-proven …

The current standard of care model for newly diagnosed fit multiple myeloma (NDMM)
patients is the sequential treatment of induction, high dose melphalan, autologous stem cell …

Multiple myeloma (MM) is a plasma cell malignancy characterized by impaired immune
surveillance mechanisms, such as altered antibody production, dysregulation of T cell and …

Despite therapeutic advances over the past decades, multiple myeloma (MM) remains a
largely incurable disease with poor prognosis in high-risk patients, and thus new treatment …

Multiple myeloma (MM) is a genetically heterogenous disease and remains mostly incurable
with a small group of patients achieving long-term disease remission. The past decade …